Harley-Davidson Inc vs IDEXX Laboratories, Inc. — how do they compare? Harley-Davidson Inc trades at $25.87 (market cap $2.78B), while IDEXX Laboratories, Inc. trades at $571.3 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 16.6× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.75% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| HOG | IDXX | |
|---|---|---|
Market Cap | $2.78B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $766.68 |
52-Week Low | $17.19 | $526.44 |
Enterprise Value | $3.19B | $47.12B |
Dividend Yield | 2.75% | — |
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.10, up 0.35% with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with an EPS beat ($0.75 vs. $0.645 expected) but revenue challenges, while raising full-year guidance. Valuation appears reasonable with P/E of 14.84 and P/S of 0.72, though profitability metrics show pressure with net margin at 4.78%.
The outlook remains cautiously optimistic with analyst consensus at $26.00 target. Key opportunities include North American sales strength and cost-cutting initiatives, while risks involve raw material costs and competitive pressures. Institutional activity shows mixed signals with recent large purchases and sales.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Trailing returns across standard periods
Latest headlines on both assets
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →